Adaptive Clinical Trials: The Promise and the Caution
Author:
- 20 February 2011
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (6) , 606-609
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Why the 1948 MRC trial of streptomycin used treatment allocation based on random numbersJournal of the Royal Society of Medicine, 2011
- Outcome-Adaptive Randomization: Is It Useful?Journal of Clinical Oncology, 2011
- The Hazards of EndpointsJNCI: Journal of the National Cancer Institute, 2010
- Bayesian clinical trials at the University of Texas M. D. Anderson Cancer CenterClinical Trials, 2009
- Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicineClinical Trials, 2008
- Bayesian clinical trialsNature Reviews Drug Discovery, 2006
- Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysisClinical Trials, 2005
- Adaptive Randomized Study of Idarubicin and Cytarabine Versus Troxacitabine and Cytarabine Versus Troxacitabine and Idarubicin in Untreated Patients 50 Years or Older With Adverse Karyotype Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Streptomycin Treatment of Pulmonary Tuberculosis: A Medical Research Council InvestigationBMJ, 1948
- ON THE LIKELIHOOD THAT ONE UNKNOWN PROBABILITY EXCEEDS ANOTHER IN VIEW OF THE EVIDENCE OF TWO SAMPLESBiometrika, 1933